News
Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...
AstraZeneca said it would invest $50 billion in U.S. production by 2030. At the core is a manufacturing plant to go somewhere in Virginia.
The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...
AstraZeneca (LSE:AZN) recently experienced a weekly price move of 2% amid announcements that could have supported its ...
Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...
The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...
Astra said its experimental drug Baxdrostat reduced the blood pressure of patients who have a treatment-resistant form of ...
AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...
The company plans to invest billions in a new drug manufacturing hub in Virginia, dedicated to chronic disease treatments, alongside additional facilities in California, Indiana, Maryland, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results